Agreed. But let's talk facts.
Let's not dredge up ancient history nor attempt to predict the future. What's worse is, it's done in a fashion that makes it sound like any one of us knows what we're talking about...
Our only source of information, albeit some question the reliability, is SNDY themselves.
At the moment we're being told they're in the ISO Audit/CE Mark process. We know that often leads to an acquisition.
We know their sales/revenue vs. operational expenditures is kind of weak, however, when taken with ISO/CE information, it seems there's something to look forward to, despite this.
At the very least, getting the Mammoview into EU & Canada, where the medical systems are such that sales should become much improved, will generate substantial revenue growth.
News 
Market Data 
Discover 
AI
